The global yeast infection treatment market was valued at US$ 6158.8 million in 2023. The market is estimated to surge at a CAGR of 5.0%, reaching a valuation of US$ 10031.3 million in 2034. The primary factors driving this market's expansion include the advent of novel fungal illnesses, as well as the rise in autoimmune disorders and yeast infections.
| Attributes | Key Insights |
|---|---|
| Anticipated Market Value (2023A) | US$ 6158.8 million |
| Estimated Yeast Infection Treatment Market Size (2024E) | US$ 6479.8 million |
| Projected Yeast Infection Treatment Market Value (2034F) | US$ 10031.3 million |
| Value-based Yeast Infection Treatment Market CAGR (2024 to 2034) | 5.0% |
Market expansion is projected to be fueled by the global economic recovery, which enables consumers to access better and higher-quality healthcare. Increasing patient awareness and knowledge of yeast infections is a buffer for market expansion through 2034.
Market growth is also anticipated to be fueled by government support for research and development activities in creating antifungal drugs. In addition, the market is expected to rise significantly due to the funding from the government for medical research & development and innovative therapies for yeast infections.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Yeast infection treatment market sales account for around 39.4% of the share globally. The market was valued at US$ 6158.8 million in 2023. The global yeast infection treatment market recorded a historic CAGR of 3.9% from 2019 to 2023.
Global yeast infection treatment market expansion is anticipated to be driven by an increasing number of yeast infection cases, particularly in women. As of 2022, around 70% of women have encountered vulvovaginal candidiasis at least once in their lives, and 8% of them have had recurrent vulvovaginal candidiasis, per NCBI studies.
Yeast infections, also known as Candida infections, have become more common worldwide. Several variables, such as weakened immune systems, broad-spectrum antibiotics, and lifestyle changes, contribute to the rising incidence of yeast infections.
Public education and awareness of yeast infections have received more attention recently. Pharmaceutical companies and healthcare providers have initiated awareness campaigns to educate the public about the symptoms and preventive actions associated with yeast infections.
Through research and development, ongoing efforts have been made to look into novel therapeutic approaches and formulations for yeast infection treatment.
Treatments for yeast infections are widely available worldwide, and access to medications and healthcare has improved for emerging economies. Population growth, urbanization, and improvements in the healthcare system are some of the factors behind this surge.
Principal Consultant
The table below highlights the anticipated growth rates of different countries. Among these, India is expected to remain a highly lucrative market for yeast infection treatment, exhibiting a CAGR of 5.8%. China and Japan are anticipated to follow with CAGRs of 5.4% and 5.7%, respectively.
| Countries | Projected CAGR (2024 to 2034) |
|---|---|
| United States | 5.2% |
| China | 5.4% |
| Germany | 4.9% |
| India | 5.8% |
| Japan | 5.7% |
The United States dominated North America’s yeast infection treatment market with a share of around 90.5% in 2022. It is expected to continue to experience the same growth rate throughout the forecast period.
Understanding population preferences is critical for pharmaceutical companies operating in the yeast infection treatment market. The United States yeast infection treatment market will likely expand due to population growth, aging population, and increasing health consciousness.
In the United States, prescription and over-the-counter antifungal drugs are frequently used to treat yeast infections. Oral antifungal treatments such as fluconazole, suppositories, and topical antifungal creams are set to be common medications in the United States.
Candida auris poses a concern to patients in healthcare facilities across Europe, particularly in Germany, because of its potential to cause epidemics and its antifungal tolerance. Due to ongoing efforts to raise national awareness of yeast infection, prevention and control measures, the market is expected to surge in Germany.
Over-the-counter (OTC) medications, such as suppositories and antifungal lotions, give people self-treatment choices. This accessibility influences the dynamics of the market as a whole.
Germany-based healthcare groups regularly participate in awareness programs to raise public knowledge of yeast infections. This details risk factors, symptoms, and the significance of consulting a medical expert for yeast infection treatment.
China reached a valuation of US$ 301.7 million, withholding a significant market share of around 28.9% by 2022. China, in particular, is home to a variety of unknown yeasts that have the potential to be pathogenic in exposed hosts.
One of the key factors influencing the market for yeast infection treatment is the regulatory landscape in China, which includes the approval procedure for new medications and therapies. Market dynamics can be affected by consumer preferences for particular brands or treatment types and the rising popularity of natural or home cures.
Economic considerations can affect the population's accessibility to treatments for yeast infections, including healthcare spending, insurance coverage, and pharmaceutical prices. China continues to lead the world in the research & development of antifungal drugs, including investigating novel compounds and treatment approaches.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below signifies leading sub-categories under the route of administration, form, and distribution channel segment categories in the yeast infection treatment market. The oral segment is expected to surge at a CAGR of 5.2% in the evaluation period. Under the form category, the tablets/ capsules segment is projected to rise at a CAGR of 5.4% by 2034.
| Route of Administration | Value-based CAGR |
|---|---|
| IV/IM | 5.4% |
| Oral | 5.2% |
Based on the route of administration, the oral segment has driven the market by holding a significant share of around 54.6% in 2022. Due to its benefits, including non-invasiveness, patient compliance, and ease of drug administration, it is the most favored method in the market.
The oral route of administration is recommended for systemic antifungal treatment since it enables convenient and patient-friendly dosage. The drug can be taken by the patient at home, and this method of delivery is frequently preferred by the patient over intravenous therapy.
When prescribing oral antifungal drugs, healthcare providers should consider patient compliance, drug interactions, and possible side effects. Furthermore, new oral antifungal medications are being introduced into the market to treat yeast infections as a result of ongoing research and development activities.
| Form | Value-based CAGR |
|---|---|
| Tablets/ Capsules | 5.4% |
| Cream / Ointments | 5.0% |
Based on form, the tablets/capsules segment has led the market by holding a remarkable share of 45.8% in 2022. Tablets are available in different shapes and have a longer shelf life. Also, they can withstand a higher dosage of an active chemical.
The specific antifungal medication, patient preferences, and the stability & bioavailability of the formulation are a handful of the elements that influence the demand for tablets and capsules. Tablets and capsules include benefits such as precise dosing, simplicity of storage, and enhanced patient compliance, which would drive sales.
| Distribution Channel | Value-based CAGR |
|---|---|
| Online Sales | 6.0% |
| Retail Pharmacies/ Drug Stores | 5.5% |
Based on distribution channels, retail pharmacies/drug stores have driven the global market, withholding a share of around 31.2% in 2022. Working long hours, drive-through facilities, and a wide variety of prescription and over-the-counter pharmaceuticals are the key drivers boosting the demand for retail pharmacies and drug stores.
Several e-commerce sites and online pharmacies let customers buy products for treating yeast infections straight from their websites. This covers popular websites such as Walmart, Amazon, and specialized online pharmacies.
Conventional merchants frequently offer an online presence that enables customers to order items for treating yeast infections and have them delivered to their homes. This covers both big-box pharmacies and independent health and wellness stores.
The market as a whole is fragmented due to the several players in the yeast infection treatment sector. In order to fulfill consumer demand and expand their client base, key firms are launching new products, forming partnerships & collaborations, and engaging in mergers & acquisitions.
Instances of key developmental strategies by leading players in the yeast infection treatment market are given below:
| Attribute | Details |
|---|---|
| Estimated Yeast Infection Treatment Market Size (2024) | US$ 6479.8 million |
| Projected Yeast Infection Treatment Market Value (2034) | US$ 10031.3 million |
| Anticipated Growth Rate (2024 to 2034) | 5.0% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; and Middle East and Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Rest of Latin America, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, GCC, South Africa, North Africa and Rest of Middle East and Africa |
| Key Market Segments Covered | Treatment Type, Indication, Route of Administration, Form, Distribution Channel, and Region |
| Key Companies Profiled | Astellas Pharma Inc.; Astra Zeneca; Abbott Laboratories; Allergan; Brundavan Laboratories Private Limited; Bayer; Corden Pharma; Merck & Co., Inc.; Novartis; Pfizer Inc.; Synmedic Laboratories; Sanofi |
The yeast infection treatment market size is estimated to reach US$ 6158.8 million in 2023.
The target market size is expected to reach US$ 10031.3 million in 2034.
The emergence of new fungal infections and increasing use of antibiotics would fuel growth.
Astellas Pharma Inc., Astra Zeneca, and Abbott Laboratories are the leading players.
The market for yeast infection treatment expanded at a CAGR of 3.9%.
Yeast infection treatment demand is set to surge at a 5.0% CAGR through 2034.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmaps
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Key Promotional Strategies by Manufacturers
4.2. Value Chain Analysis
4.3. Product USP Analysis
4.4. Product Adoption Analysis
4.5. PESTEL Analysis
4.6. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Antifungal Treatment Market Outlook
5.2. Forecast Factors - Relevance and Impact
5.2.1. Top Companies Historical Growth
5.2.2. Prevalence of Infectious Diseases
5.2.3. Increasing Number of Yeast Infections in Women
5.2.4. Government Campaigns
5.2.5. Rising Autoimmune Diseases Prevalence
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Value (US$ million) Analysis, 2019 to 2023
6.2. Current and Future Market Value (US$ million) Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ million) Analysis, by Treatment Type, 2019 to 2023
7.3. Current and Future Market Size (US$ million) Analysis and Forecast, by Treatment Type, 2024 to 2034
7.3.1. Azoles
7.3.2. Polygene
7.3.3. Echinocandin
7.3.4. Others
7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) Analysis, by Indication, 2019 to 2023
8.3. Current and Future Market Size (US$ million) Analysis and Forecast, by Indication, 2024 to 2034
8.3.1. Genital Candidiasis
8.3.2. Invasive Candidiasis
8.3.3. Oropharyngeal/Esophageal Candidiasis (Thrush)
8.3.4. Others
8.4. Market Attractiveness Analysis, by Indication
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) Analysis, By Route of Administration, 2019 to 2023
9.3. Current and Future Market Size (US$ million) Analysis and Forecast, by Route of Administration, 2024 to 2034
9.3.1. Oral
9.3.2. Topical
9.3.3. IV/IM
9.3.4. Other
9.4. Market Attractiveness Analysis, by Route of Administration
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Form
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ million) Analysis, By Form, 2019 to 2023
10.3. Current and Future Market Size (US$ million) Analysis and Forecast, by Form, 2024 to 2034
10.3.1. Powders
10.3.2. Creams/Ointments
10.3.3. Tablets/Capsules
10.3.4. Others
10.4. Market Attractiveness Analysis, by Form
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ million) Analysis, By Distribution Channel, 2019 to 2023
11.3. Current and Future Market Size (US$ million) Analysis and Forecast, by Distribution Channel, 2024 to 2034
11.3.1. Retail Pharmacies/Drug Stores
11.3.2. Hospital Pharmacies
11.3.3. Specialty Stores
11.3.4. Online Sales
11.3.5. Others (Hypermarkets/ Conventional Stores)
11.4. Market Attractiveness Analysis, by Distribution Channel
12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
12.1. Introduction
12.2. Historical Market Size (US$ million) Analysis, by Region, 2019 to 2023
12.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis, by Region
13. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ million) Analysis Trend Analysis, by Market Taxonomy, 2019 to 2023
13.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034
13.3.1. By Country
13.3.1.1. United States
13.3.1.2. Canada
13.3.2. By Treatment Type
13.3.3. By Indication
13.3.4. By Route of Administration
13.3.5. By Form
13.3.6. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Treatment Type
13.4.3. By Indication
13.4.4. By Route of Administration
13.4.5. By Form
13.4.6. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis and Forecast
13.7.1. United States Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast, by Market Taxonomy
13.7.1.2.1. By Treatment Type
13.7.1.2.2. By Indication
13.7.1.2.3. By Route of Administration
13.7.1.2.4. By Form
13.7.1.2.5. By Distribution Channel
13.7.2. Canada Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast, by Market Taxonomy
13.7.2.2.1. By Treatment Type
13.7.2.2.2. By Indication
13.7.2.2.3. By Route of Administration
13.7.2.2.4. By Form
13.7.2.2.5. By Distribution Channel
14. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ million) Analysis Trend Analysis, by Market Taxonomy, 2019 to 2023
14.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Treatment Type
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Form
14.3.6. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Treatment Type
14.4.3. By Indication
14.4.4. By Route of Administration
14.4.5. By Form
14.4.6. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis and Forecast
14.7.1. Mexico Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast, by Market Taxonomy
14.7.1.2.1. By Treatment Type
14.7.1.2.2. By Indication
14.7.1.2.3. By Route of Administration
14.7.1.2.4. By Form
14.7.1.2.5. By Distribution Channel
14.7.2. Brazil Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast, by Market Taxonomy
14.7.2.2.1. By Treatment Type
14.7.2.2.2. By Indication
14.7.2.2.3. By Route of Administration
14.7.2.2.4. By Form
14.7.2.2.5. By Distribution Channel
14.7.3. Argentina Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast, by Market Taxonomy
14.7.3.2.1. By Treatment Type
14.7.3.2.2. By Indication
14.7.3.2.3. By Route of Administration
14.7.3.2.4. By Form
14.7.3.2.5. By Distribution Channel
15. Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ million) Analysis Trend Analysis, by Market Taxonomy, 2019 to 2023
15.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Treatment Type
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Form
15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Treatment Type
15.4.3. By Indication
15.4.4. By Route of Administration
15.4.5. By Form
15.4.6. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis and Forecast
15.7.1. Germany Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast, by Market Taxonomy
15.7.1.2.1. By Treatment Type
15.7.1.2.2. By Indication
15.7.1.2.3. By Route of Administration
15.7.1.2.4. By Form
15.7.1.2.5. By Distribution Channel
15.7.2. Italy Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast, by Market Taxonomy
15.7.2.2.1. By Treatment Type
15.7.2.2.2. By Indication
15.7.2.2.3. By Route of Administration
15.7.2.2.4. By Form
15.7.2.2.5. By Distribution Channel
15.7.3. France Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast, by Market Taxonomy
15.7.3.2.1. By Treatment Type
15.7.3.2.2. By Indication
15.7.3.2.3. By Route of Administration
15.7.3.2.4. By Form
15.7.3.2.5. By Distribution Channel
15.7.4. United Kingdom Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast, by Market Taxonomy
15.7.4.2.1. By Treatment Type
15.7.4.2.2. By Indication
15.7.4.2.3. By Route of Administration
15.7.4.2.4. By Form
15.7.4.2.5. By Distribution Channel
15.7.5. Spain Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast, by Market Taxonomy
15.7.5.2.1. By Treatment Type
15.7.5.2.2. By Indication
15.7.5.2.3. By Route of Administration
15.7.5.2.4. By Form
15.7.5.2.5. By Distribution Channel
15.7.6. BENELUX Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast, by Market Taxonomy
15.7.6.2.1. By Treatment Type
15.7.6.2.2. By Indication
15.7.6.2.3. By Route of Administration
15.7.6.2.4. By Form
15.7.6.2.5. By Distribution Channel
15.7.7. Russia Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast, by Market Taxonomy
15.7.7.2.1. By Treatment Type
15.7.7.2.2. By Indication
15.7.7.2.3. By Route of Administration
15.7.7.2.4. By Form
15.7.7.2.5. By Distribution Channel
16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Distribution Channel (US$ million) Analysis Trend Analysis, by Market Taxonomy, 2019 to 2023
16.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Treatment Type
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Form
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Treatment Type
16.4.2. By Indication
16.4.3. By Route of Administration
16.4.4. By Form
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis and Forecast
16.7.1. China Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast, by Market Taxonomy
16.7.1.2.1. By Treatment Type
16.7.1.2.2. By Indication
16.7.1.2.3. By Route of Administration
16.7.1.2.4. By Form
16.7.1.2.5. By Distribution Channel
16.7.2. Japan Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast, by Market Taxonomy
16.7.2.2.1. By Treatment Type
16.7.2.2.2. By Indication
16.7.2.2.3. By Route of Administration
16.7.2.2.4. By Form
16.7.2.2.5. By Distribution Channel
16.7.3. South Korea Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast, by Market Taxonomy
16.7.3.2.1. By Treatment Type
16.7.3.2.2. By Indication
16.7.3.2.3. By Route of Administration
16.7.3.2.4. By Form
16.7.3.2.5. By Distribution Channel
17. South Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ million) Analysis Trend Analysis, by Market Taxonomy, 2019 to 2023
17.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Treatment Type
17.3.3. By Indication
17.3.4. By Route of Administration
17.3.5. By Form
17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Treatment Type
17.4.3. By Indication
17.4.4. By Route of Administration
17.4.5. By Form
17.4.6. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis and Forecast
17.7.1. India Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast, by Market Taxonomy
17.7.1.2.1. By Treatment Type
17.7.1.2.2. By Indication
17.7.1.2.3. By Route of Administration
17.7.1.2.4. By Form
17.7.1.2.5. By Distribution Channel
17.7.2. Indonesia Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast, by Market Taxonomy
17.7.2.2.1. By Treatment Type
17.7.2.2.2. By Indication
17.7.2.2.3. By Route of Administration
17.7.2.2.4. By Form
17.7.2.2.5. By Distribution Channel
17.7.3. Malaysia Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast, by Market Taxonomy
17.7.3.2.1. By Treatment Type
17.7.3.2.2. By Indication
17.7.3.2.3. By Route of Administration
17.7.3.2.4. By Form
17.7.3.2.5. By Distribution Channel
17.7.4. Thailand Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast, by Market Taxonomy
17.7.4.2.1. By Treatment Type
17.7.4.2.2. By Indication
17.7.4.2.3. By Route of Administration
17.7.4.2.4. By Form
17.7.4.2.5. By Distribution Channel
18. Oceania Market 2019 to 2023 and Forecast 2024 to 2034
18.1. Introduction
18.2. Historical Market Size (US$ million) Analysis Trend Analysis, by Market Taxonomy, 2019 to 2023
18.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Treatment Type
18.3.3. By Indication
18.3.4. By Route of Administration
18.3.5. By Form
18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Treatment Type
18.4.3. By Indication
18.4.4. By Route of Administration
18.4.5. By Form
18.4.6. By Distribution Channel
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country Level Analysis and Forecast
18.7.1. Australia Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast, by Market Taxonomy
18.7.1.2.1. By Treatment Type
18.7.1.2.2. By Indication
18.7.1.2.3. By Route of Administration
18.7.1.2.4. By Form
18.7.1.2.5. By Distribution Channel
18.7.2. New Zealand Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast, by Market Taxonomy
18.7.2.2.1. By Treatment Type
18.7.2.2.2. By Indication
18.7.2.2.3. By Route of Administration
18.7.2.2.4. By Form
18.7.2.2.5. By Distribution Channel
19. Middle East and Africa (MEA) Market Analysis 2019 to 2023 and Forecast 2024 to 2034
19.1. Introduction
19.2. Historical Market Size (US$ million) Analysis Trend Analysis, by Market Taxonomy, 2019 to 2023
19.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Treatment Type
19.3.3. By Indication
19.3.4. By Route of Administration
19.3.5. By Form
19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Treatment Type
19.4.2. By Indication
19.4.3. By Route of Administration
19.4.4. By Form
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Country Level Analysis and Forecast
19.7.1. GCC Countries Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast, by Market Taxonomy
19.7.1.2.1. By Treatment Type
19.7.1.2.2. By Indication
19.7.1.2.3. By Route of Administration
19.7.1.2.4. By Form
19.7.1.2.5. By Distribution Channel
19.7.2. Türkiye Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast, by Market Taxonomy
19.7.2.2.1. By Treatment Type
19.7.2.2.2. By Indication
19.7.2.2.3. By Route of Administration
19.7.2.2.4. By Form
19.7.2.2.5. By Distribution Channel
19.7.3. South Africa Market Analysis
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast, by Market Taxonomy
19.7.3.2.1. By Treatment Type
19.7.3.2.2. By Indication
19.7.3.2.3. By Route of Administration
19.7.3.2.4. By Form
19.7.3.2.5. By Distribution Channel
19.7.4. North Africa Market Analysis
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast, by Market Taxonomy
19.7.4.2.1. By Treatment Type
19.7.4.2.2. By Indication
19.7.4.2.3. By Route of Administration
19.7.4.2.4. By Form
19.7.4.2.5. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis, by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Abbott Laboratories
21.3.1.1. Overview
21.3.1.2. Treatment Type Portfolio
21.3.1.3. Sales Footprint
21.3.1.4. Key Financials
21.3.1.5. SWOT Analysis
21.3.1.6. Strategy Overview
21.3.1.6.1. Marketing Strategy
21.3.1.6.2. Treatment Type Strategy
21.3.1.6.3. Channel Strategy
21.3.2. Astellas Pharma Inc.
21.3.3. Astra Zeneca
21.3.4. Allergan
21.3.5. Brundavan Laboratories Private Limited
21.3.6. Bayer
21.3.7. Corden Pharma
21.3.8. Merck & Co., Inc.
21.3.9. Novartis
21.3.10. Pfizer Inc.
21.3.11. Synmedic Laboratories
21.3.12. Sanofi
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Yeast Infection Treatment Market
